methylphenidate prolonged release tablet - 12 hrs acting / Generic mfg. - LARVOL DELTA

BATIR: Benefits of ADHD Treatment in Detained People (clinicaltrials.gov) - P3 | N=150 | Recruiting | Sponsor: Stéphanie Baggio | Trial completion date: Oct 2026 ➔ Oct 2027 | Trial primary completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Glutamatergic Enhancement Using As-Needed Dextromethorphan and Piracetam in a Stimulant-Partially Responsive Adult With ADHD: A Single-Case Report. (PubMed, Cureus) - "Emerging evidence points to disrupted dopamine-glutamate coupling and insufficient synaptic pruning as contributors to these persistent deficits, suggesting a potential role for glutamatergic modulation inspired by ketamine's rapid neuroplastic effects. This report describes a 25-year-old man with childhood-onset ADHD who, despite trials of high-dose methylphenidate (up to 72 mg) and lisdexamfetamine (up to 80 mg), continued to report daytime lethargy, mental sluggishness, irritability, and oversleeping while on moderate-dose extended-release methylphenidate (Concerta 36-54 mg daily)...This single-case observation suggests that low-dose dextromethorphan, through brief N-methyl-D-aspartate modulation, combined with piracetam's α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) potentiation, may enhance methylphenidate's modest glutamate release, potentially promoting an AMPA-favorable plasticity state that could help mitigate pruning-related..."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Fatigue • Psychiatry

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer (clinicaltrials.gov) - P2 | N=68 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Dec 2025 ➔ Dec 2028

Trial completion date • CNS Disorders • Hematological Malignancies • Oncology • Sleep Disorder • Solid Tumor

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body (clinicaltrials.gov) - P1 | N=42 | Not yet recruiting | Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

New P1 trial • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Local Data, National Crisis: Pediatric ADHD Treatment Disruptions Amid 2024 Stimulant Shortages (AACAP 2025) - "All data used were deidentified. Of 51 total encounters, the most commonly affected medication was Vyvanse (n = 20, 39.2%), followed by Concerta (n = 14, 27.5%), Focalin XR (n = 10, 19.6%), Ritalin (n = 4, 7.8%), and Adderall (n = 3, 5.9%). These findings provide a real-time clinical snapshot of how stimulant shortages disrupted ADHD care among vulnerable pediatric populations. Even when prescriptions were ultimately filled, the process introduced delays, suboptimal substitutions, and increased burdens on families and providers. These disruptions risk exacerbating symptoms such as impulsivity, inattention, and emotional dysregulation in youth."

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Pediatrics • Psychiatry

The Role of Early Exposure Metrics (pAUC0-3h and Cmax,0-3h) in Assessing the Bioequivalence of Methylphenidate Extended-release Products_A Sensitivity Analysis. (PubMed, AAPS J) - "To ensure bioequivalence (BE) for products such as Concerta and Ritalin LA, both the FDA and EMA recommend the use of pAUC0-3h, with the EMA additionally suggesting the inclusion of Cmax,0-3h. Although Cmax,0-3h exhibited high sensitivity in products with dual first-order absorption, its responsiveness remained inferior to pAUC0-3h. These findings support the use of pAUC0-3h as the primary early exposure metric for therapeutic equivalence assessment and suggest that Cmax,0-3h may not provide further discriminatory value beyond that of pAUC0-3h."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Comparison between atomoxetine and OROS methylphenidate as an adjunctive to SSRIs in adult ADHD with comorbid partially responsive major depression (ECNP 2025) - "No other psychotropic drugs were permitted during the study period, except for benzodiazepines (up to 2 mg/day of lorazepam or equivalent). Our findings suggest that ATX and MPH can be used as adjunctive treatments in adults with ADHD and comorbid partially responsive MDD. The efficacy and tolerability of ATX and MPH in adults with ADHD did not differ significantly. Further well-designed studies should be conducted to draw a definitive conclusion and to better understand the relationship between ADHD and depressive disorders."

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • General Anxiety Disorder • Major Depressive Disorder • Mood Disorders • Psychiatry

Challenges in the Treatment of Narcolepsy and the Positive Impact of Acetyl-L-Carnitine: A Case-Based Review with 20-Year Follow-Up (WSS 2025) - "Initial pharmacologic management included antidepressants, Modafinil, Armodafinil, Adderall, Concerta, Jornay, Vyvanse, and sodium oxybate (Xyrem). This case highlights the multifaceted challenges in narcolepsy management and proposes acetyl-L-carnitine as a potential adjuvant therapy in refractory cases. Given its safety profile and observed benefit in this case, ALCAR warrants further investigation through controlled clinical trials."

Clinical • Review • Barrett Esophagus • Cataplexy • CNS Disorders • Excessive Daytime Sleepiness • Gastrointestinal Disorder • Mental Retardation • Metabolic Disorders • Mood Disorders • Narcolepsy • Psychiatry • Sleep Disorder

Treatment Considerations in Co-morbid Schizophrenia and Narcolepsy: A Case Report (WSS 2025) - "Some alertness promoting medications used in narcolepsy treatment, such as modafinil, methylphenidate and amphetamine, may exacerbate psychosis by increasing dopamine activity...He was previously intolerant to modafinil (emotional numbing) and Concerta (appetite suppression) as per chart review.Paliperidone was effective for psychosis but worsened sleepiness, which was disabling... In conclusion, some traditional stimulants may worsen psychosis in PWN. Pitolisant, an inverse H3 agonist, which does not theoretically affect dopamine pathways, may be a suitable treatment for sleepiness and cataplexy in comorbid psychosis."

Case report • Clinical • Cataplexy • CNS Disorders • Narcolepsy • Psychiatry • Schizophrenia • Sleep Disorder

Pharmacokinetics and Bioequivalence of a Novel Extended-Release Formulation of Methylphenidate Hydrochloride for Attention-Deficit/Hyperactivity Disorder. (PubMed, Clin Pharmacol Drug Dev) - "In the first trial (N = 60), a single 72-mg tablet of ODX-methylphenidate ER was compared to two 36-mg tablets of OROS-methylphenidate ER, while in the second trial (N = 36), a single 54-mg tablet of ODX-methylphenidate ER was compared to a 54-mg tablet of OROS-methylphenidate ER. Statistical bioequivalence between the 2 formulations was confirmed for maximum drug concentration, area under the concentration-time curve from time 0 to 3 hours after dosing (AUC0-3 h), AUC from 3 to 7 hours after dosing, AUC from 7 to 12 hours after dosing, and AUC from time 0 extrapolated to infinity in both trials. Safety and tolerability were similar for both products and in both trials, with no serious adverse events reported."

Journal • PK/PD data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Drugs for ADHD. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Structural basis for Salmonella infection by two Microviridae phages. (PubMed, Commun Biol) - "Here, we identify two Microviridae phages, PJNS001 and PJNS002, with different host receptor dependencies, and determine their cryo-EM structures at 2.68 Å and 2.59 Å resolution, respectively...Structural analysis and in situ visualization reveal spike protein features and host-attachment intermediates, informing host specificity. Together, these findings advance our understanding of Microviridae infection mechanisms and provide a structural framework for rational phage design against antibiotic-resistant pathogens."

Journal • Infectious Disease

"The disruptive effects of methylphenidate treatment on circadian rhythm in adult female zebrafish and epigenetic transmission of its negative effects to offspring.". (PubMed, Physiol Behav) - "Numerous medications have been developed to manage ADHD, with methylphenidate (commonly known as Ritalin or Concerta) being the most widely used active compound. In the offspring of the next generation, it was observed that the telomere length inherited at birth was shorter when treated with MPH only. Also, methylation in the FOXM1 is observed in MPH-only treatment group, and compensated with combinational treatments for melatonin and oxytocin."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Inflammation • Mood Disorders • Psychiatry • Sleep Disorder • FOXM1

Complex ADHD in a Child With Tic Disorder. (PubMed, J Dev Behav Pediatr) - "He is currently prescribed OROS methylphenidate 54 mg capsules once daily in the morning, which he has taken for 3 years. There was no accompanying vocalization with this movement.His parents are requesting a medication adjustment or change. What would you do?"

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Behavior Disorders • CNS Disorders • Cognitive Disorders • Mood Disorders • Movement Disorders • Psychiatry • Tic Disorders • Tourette Syndrome

CHEC2023-296: Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children. (clinicaltrials.gov) - P=N/A | N=210 | Recruiting | Sponsor: Lei Lei, MD | Trial completion date: Aug 2025 ➔ Dec 2025 | Trial primary completion date: Aug 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Rabbit Syndrome: A Rare Iatrogenic Tremor Due to Discontinuation of Aripiprazole (APA 2025) - "Patient was initially managed with Effexor and Buspar for anxiety before switching to Lexapro and Abilify in 2020...Patient's Abilify was initially reduced to 5mg daily, Requip 1mg nightly for RLS and Concerta 54mg daily for ADHD...Management includes tapering off antipsychotics, switching medications, or using anticholinergics like Benztropine or Trihexiphenidyl. ß-blockers may also provide relief. Further research is necessary to better understand and treat Rabbit syndrome."

Preclinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Infectious Disease • Mood Disorders • Movement Disorders • Psychiatry • DRD2

Methylphenidate for Ptsd and Stroke Veterans (clinicaltrials.gov) - P1/2 | N=20 | Completed | Sponsor: VA Office of Research and Development | Recruiting ➔ Completed | Phase classification: P2 ➔ P1/2 | N=60 ➔ 20 | Trial completion date: Sep 2026 ➔ May 2025 | Trial primary completion date: Sep 2026 ➔ May 2025

Enrollment change • Phase classification • Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Stimulant Effects on Disruptive Behavior (clinicaltrials.gov) - P4 | N=10 | Recruiting | Sponsor: Matthew J O'Brien, PhD, BCBA-D | Trial completion date: Jan 2025 ➔ Aug 2027 | Trial primary completion date: Jan 2025 ➔ Mar 2027

Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Behavior Disorders • CNS Disorders • Psychiatry

CHEC2023-296: Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children. (clinicaltrials.gov) - P=N/A | N=200 | Recruiting | Sponsor: Lei Lei, MD | Trial completion date: Feb 2025 ➔ Aug 2025 | Trial primary completion date: Feb 2025 ➔ Aug 2025

Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (clinicaltrials.gov) - P2 | N=175 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Feb 2025 ➔ Sep 2026 | Trial primary completion date: Feb 2025 ➔ Sep 2026

Trial completion date • Trial primary completion date • Fatigue • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

The Effects of Methylphenidate on Symptomatology in Individuals With Borderline Personality Disorder (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Tanta University

New P1 trial • Borderline Personality Disorder • CNS Disorders • Mood Disorders • Personality Disorder

BAT: Biomarkers of ADHD Treatment Response (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: Boston Children's Hospital | Recruiting ➔ Completed | N=30 ➔ 16 | Trial completion date: Aug 2025 ➔ Mar 2024 | Trial primary completion date: Jul 2024 ➔ Mar 2024

Biomarker • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Methylphenidate abuse and misuse in patients affected with a psychiatric disorder and a substance use disorder: a systematic review. (PubMed, Front Psychiatry) - "The following search strategy was used: TITLE-ABS-KEY (methylphenidate OR Ritalin OR Concerta) AND TITLE-ABS-KEY (abuse OR misuse OR dependency OR addiction) AND TITLE-ABS-KEY (dual diagnosis OR comorbid psychiatric disorder OR psychiatric disorder AND substance use disorder). Integrated therapeutic approaches and stricter prescription monitoring are recommended to mitigate misuse risks. https://www.crd.york.ac.uk/prospero/, identifier CRD42024576724."

Journal • Review • Addiction (Opioid and Alcohol) • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Behavior Disorders • Cardiovascular • CNS Disorders • Depression • Gastrointestinal Disorder • Major Depressive Disorder • Mental Retardation • Mood Disorders • Nicotine Addiction • Personality Disorder • Psychiatry • Substance Abuse

Comparison of the real-world safety of two different long-acting methylphenidate formulations (Medikinet® MR and Concerta®) - a Danish nationwide register-based cohort study. (PubMed, Scand J Child Adolesc Psychiatr Psychol) - "The sensitivity analysis produced results consistent with those obtained in the main analysis. The results of this population-based cohort study indicate that Medikinet® MR and Concerta® have comparable real-world safety profiles."

Journal • Real-world • Real-world evidence • ADHD (Impulsive Aggression) • Anorexia • Attention Deficit Hyperactivity Disorder • CNS Disorders • Pediatrics • Psychiatry